Novartis NVS -1.01% unveiled new findings from its PSMAddition study, highlighting the effectiveness of Pluvicto when used alongside standard treatment for patients with PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC). These results were shared in a rapid oral presentation at the 2026 American Urological Association Annual Meeting.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.